BR0212894A - Derivados de sulfeto de diarila, sais resultantes e agentes imunosupressores utilizando os mesmos - Google Patents

Derivados de sulfeto de diarila, sais resultantes e agentes imunosupressores utilizando os mesmos

Info

Publication number
BR0212894A
BR0212894A BR0212894-2A BR0212894A BR0212894A BR 0212894 A BR0212894 A BR 0212894A BR 0212894 A BR0212894 A BR 0212894A BR 0212894 A BR0212894 A BR 0212894A
Authority
BR
Brazil
Prior art keywords
same
derivatives
resulting salts
immunosuppressive agents
diaryl sulfide
Prior art date
Application number
BR0212894-2A
Other languages
English (en)
Other versions
BRPI0212894B1 (pt
BRPI0212894B8 (pt
Inventor
Yasushi Kohno
Naoki Ando
Kazuhiko Kuriyama
Satoru Iwanami
Shinji Kudou
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of BR0212894A publication Critical patent/BR0212894A/pt
Publication of BRPI0212894B1 publication Critical patent/BRPI0212894B1/pt
Publication of BRPI0212894B8 publication Critical patent/BRPI0212894B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DERIVADOS DE SULFETO DE DIARILA, SAIS RESULTANTES E AGENTES IMUNOSUPRESSORES UTILIZANDO OS MESMOS". A presente invenção fornece derivados do sulfeto de diarila que exibem efeitos imunosupressores significativos com menos efeitos colaterais. Os derivados da diarila da atual invenção são representados pela seguinte fórmula geral (1): (Um exemplo é 2-amino-2-[4-(3-benziloxilatiofenil)-2-clorofenil]) propil-1,3-propanodiol.
BRPI0212894A 2001-09-27 2002-09-25 composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica BRPI0212894B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001297411 2001-09-27
JP2001-297411 2001-09-27
JP2002-216192 2002-07-25
JP2002216192 2002-07-25
PCT/JP2002/009865 WO2003029205A1 (fr) 2001-09-27 2002-09-25 Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur

Publications (3)

Publication Number Publication Date
BR0212894A true BR0212894A (pt) 2004-10-13
BRPI0212894B1 BRPI0212894B1 (pt) 2019-07-30
BRPI0212894B8 BRPI0212894B8 (pt) 2021-05-25

Family

ID=26623111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212894A BRPI0212894B8 (pt) 2001-09-27 2002-09-25 composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica

Country Status (15)

Country Link
US (1) US6960692B2 (pt)
EP (1) EP1431284B1 (pt)
JP (2) JP4217620B2 (pt)
KR (1) KR100913269B1 (pt)
CN (1) CN1329372C (pt)
AU (1) AU2002332289B2 (pt)
BR (1) BRPI0212894B8 (pt)
CA (1) CA2461212C (pt)
CY (1) CY1107272T1 (pt)
DE (1) DE60223699T2 (pt)
DK (1) DK1431284T3 (pt)
ES (1) ES2292809T3 (pt)
MX (1) MXPA04002679A (pt)
PT (1) PT1431284E (pt)
WO (1) WO2003029205A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435946B8 (en) * 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
MXPA05003080A (es) 2002-09-19 2005-06-15 Kyorin Seiyaku Kk Derivado de amino alcohol, sales de los mismos y agentes inmunosupresores.
EP2251007A3 (en) 2002-09-24 2011-03-23 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
KR101367574B1 (ko) 2003-04-08 2014-02-25 미쓰비시 타나베 파마 코퍼레이션 Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
ES2383298T3 (es) * 2003-04-30 2012-06-20 Novartis Ag Derivados del amino-propanol como moduladores del receptor esfingosina-1-fosfato
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
EP1755680A1 (en) 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
DK1772145T3 (da) * 2004-07-16 2011-05-30 Kyorin Seiyaku Kk Fremgangsmåde til effektiv anvendelse af medicin og fremgangsmåde til forebyggelse af bivirkninger
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
US20080096972A1 (en) 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストの投与レジメン
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
DK1926483T3 (da) * 2005-09-09 2011-03-14 Novartis Ag Behandling af autoimmune sygdomme
JP5044919B2 (ja) * 2005-10-07 2012-10-10 Ｊｎｃ株式会社 ベンゼン環にアルキル基を有する化合物、この化合物を含有する液晶組成物およびこの液晶組成物を含有する液晶表示素子
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
WO2007126042A1 (ja) * 2006-04-28 2007-11-08 Mitsubishi Tanabe Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
AU2007282556B2 (en) * 2006-08-08 2012-03-08 Kyorin Pharmaceutical Co., Ltd. Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
SI2058317T1 (sl) 2006-08-08 2014-01-31 Kyorin Pharmaceutical Co., Ltd. Derivat estra aminofosforjeve kisline in S1P receptorski modulator, ki ga vsebuje kot učinkovino
CN101674819A (zh) 2007-05-04 2010-03-17 诺瓦提斯公司 S1p受体调节剂的用途
AU2008262871B2 (en) 2007-06-14 2013-11-07 Mitsubishi Tanabe Pharma Corporation Amine compound and pharmaceutical use thereof
TW200927142A (en) 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
US8476305B2 (en) * 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
EP2278960B2 (en) 2008-03-17 2019-11-13 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
US9493410B2 (en) * 2008-03-24 2016-11-15 Kyorin Pharmaceutical Co., Ltd. Method for crystallization of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride
WO2009142194A1 (ja) * 2008-05-19 2009-11-26 杏林製薬株式会社 光学活性アミノアルコール誘導体の製造方法
CN102123735A (zh) * 2008-05-20 2011-07-13 杏林制药株式会社 诱导缓解维持剂
KR20210099206A (ko) 2008-07-23 2021-08-11 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
NZ591001A (en) 2008-08-27 2012-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
PL2452944T3 (pl) 2009-07-09 2015-03-31 Kyorin Seiyaku Kk Pochodne difenylosiarczkowe i leki je zawierające jako składniki aktywne
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
MX2012012925A (es) 2010-05-06 2012-12-17 Novartis Ag Regimen de dosificacion de derivados de sulfuro de diarilo.
CA2795394A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Treatment of autoimmune diseases
WO2012015758A2 (en) * 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
WO2012073249A1 (en) 2010-12-01 2012-06-07 Arch Pharmalabs Limited A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs.
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN104379562B (zh) * 2012-04-18 2016-06-01 杏林制药株式会社 4-(3-苄氧基苯基硫基)-2-氯-1-(3-硝基丙基)苯晶体
JP6194306B2 (ja) 2012-04-23 2017-09-06 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
CN103113270A (zh) * 2012-11-26 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 一种4-（3-苄氧基-苯基硫烷基）-2-氯-1-乙烯基苯的合成方法
SI2958624T1 (sl) 2013-02-20 2021-07-30 Priothera Limited Zdravljenje bolezni presadka proti gostitelju pri transplantiranih pacientih
JP6294872B2 (ja) 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN112512516A (zh) 2018-07-27 2021-03-16 普瑞奥治疗有限公司 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
WO2023156506A1 (en) 2022-02-16 2023-08-24 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant

Also Published As

Publication number Publication date
BRPI0212894B1 (pt) 2019-07-30
US6960692B2 (en) 2005-11-01
BRPI0212894B8 (pt) 2021-05-25
JP2009040794A (ja) 2009-02-26
EP1431284B1 (en) 2007-11-21
AU2002332289B2 (en) 2007-05-10
EP1431284A4 (en) 2006-03-01
US20040254222A1 (en) 2004-12-16
PT1431284E (pt) 2008-01-21
EP1431284A1 (en) 2004-06-23
DE60223699T2 (de) 2008-10-30
JP4217620B2 (ja) 2009-02-04
CA2461212A1 (en) 2003-04-10
DE60223699D1 (en) 2008-01-03
WO2003029205A1 (fr) 2003-04-10
CY1107272T1 (el) 2012-11-21
JPWO2003029205A1 (ja) 2005-01-13
ES2292809T3 (es) 2008-03-16
CN1561331A (zh) 2005-01-05
JP4917589B2 (ja) 2012-04-18
DK1431284T3 (da) 2008-02-18
CN1329372C (zh) 2007-08-01
KR20040037107A (ko) 2004-05-04
MXPA04002679A (es) 2004-07-30
KR100913269B1 (ko) 2009-08-21
CA2461212C (en) 2010-08-17

Similar Documents

Publication Publication Date Title
BR0212894A (pt) Derivados de sulfeto de diarila, sais resultantes e agentes imunosupressores utilizando os mesmos
DE60235900D1 (de) Osuppressivum
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR9912571A (pt) Derivado de diamida de ácido dicarboxìlicoheterocìclico fundido, herbicida, e, processo paraa utilização de um herbicida
BR0211690A (pt) Composição de glifosato e método de fabricação da mesma
BR0314455A (pt) Derivados de aminoálcool, seus sais e agentes imunosupressores
BR0206943A (pt) Inibidores de fosfodiesterase 4
BR0214378A (pt) Composições herbicidas contendo benzoilpirazóis e protetores
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
BR0206501A (pt) Inibidores de cruzipaìna e outras cisteìna proteases
BRPI0601766A (pt) composições contendo aminas e seu uso
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
BR0110689A (pt) Composição fungicida, e, métodos para intensificar a atividade fungicida de etaboxam, e para controlar fitopatógenos indesejados
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
BR0210170A (pt) Agente herbicida contendo benzoilpirazol e protetores
BR0215067A (pt) Piridoquinoxalinas antivirais
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
FI962491A0 (fi) Alpha-2-adrenoseptoriagonisteina käyttökelpoisia 6-(2-imidatsolinyyliamino)kinolinyyliyhdisteitä
BR9910112A (pt) Métodos para a inibição de mrp1
BRPI0515962A (pt) agentes colorantes contendo corantes à base de indazolina tiazolazo catiÈnico
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
BR9909497A (pt) Métodos para inibição da mrp1
BR9915503A (pt) Mistura fungicida, processo para o controle de fungos nocivos, e, uso do composto.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: KYORIN PHARMACEUTICAL CO., LTD. (JP)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2689 DE 19-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.